← Back to Search
Treatment Ethics, Quality Of Life And Health Economics In The Management Of Hematopoietic Malignancies In Older Patients
Published 2015 · Medicine
Download PDFAnalyze on Scholarcy
The prevalence of diseases such as AML or myelodysplastic syndromes increases with the aging of the population. Only intensive chemotherapy or hematopoietic cell transplantation have curative potential. However, comorbid conditions may interfere with effective therapy. Although transplantation following low-intensity conditioning is being carried out in patients even in their 70s, these are highly selected patients, and the data cannot be extrapolated to the population at large. Further, such a therapy in older individuals may be associated with considerable morbidity and the need for prolonged hospitalization and rehabilitation, stressing the system and draining family resources. As the focus of many older individuals is on quality of life, it is important to emphasize that, for various advanced malignancies, emerging data indicate that quality of life may be better and survival may be longer with palliative care. A re-assessment of treatment decisions in older patients is in order. We tend to 'oversell', and particularly older patients do not have a full understanding of the impact of the proposed therapy on their lives. Our conversations with these patients must include a discussion of supportive/palliative care and must address end-of-life issues. Talking about death may mean talking about life.
This paper references
Mastering Communication with Seriously Ill Patients: INDEX
A. Back (2009)
Vulnérabilité en hématologie
D. Bordessoule (2013)
Reshaping US health care: from competition and confiscation to cooperation and mobilization.
D. Berwick (2014)
La mort de l'autre
S. Sicard (2005)
Therapy for Hematologic Cancers in Older Patients, Quality of Life, and Health Economics: Difficult Decisions.
H. Deeg (2015)
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.
F. Ostronoff (2015)
Rethinking Research Ethics
R. Rhodes (2010)
Senescent Cells, Tumor Suppression, and Organismal Aging: Good Citizens, Bad Neighbors
J. Campisi (2005)
How and why US health care differs from that in other OECD countries.
V. Fuchs (2013)
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
M. Sorror (2011)
A prognostic score for patients with lower risk myelodysplastic syndrome
G. Garcia-Manero (2008)
CHAPTER 39 – Chronic graft-versus-host disease
M. E. Flowers (2009)
Revised international prognostic scoring system for myelodysplastic syndromes.
P. Greenberg (2012)
How I assess comorbidities before hematopoietic cell transplantation.
M. Sorror (2013)
Reduced mortality after allogeneic hematopoietic-cell transplantation.
T. Gooley (2010)
Being Mortal: Medicine and What Matters in the End
D. Cusciano (2017)
Discussing Treatment Preferences With Patients Who Want Everything
T. Quill (2009)
Troubled voices : stories of ethics and illness
R. Zaner (1993)
Clinical practice. Depression in the elderly.
W. Taylor (2014)
The role of quizartinib in the treatment of acute myeloid leukemia
F. Ostronoff (2013)
Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.
N. Khera (2012)
Reframing the Goals of Care Conversation: “We're in a Different Place”
L. BackAnthony (2014)
The insurance value of Medicare.
Katherine Baicker (2012)
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
M. Bornhauser (2003)
Mastering Communication with Seriously Ill Patients: Balancing Honesty with Empathy and Hope
A. Back (2009)
Hematopoietic stem cell transplantation : in clinical practice
J. Treleaven (2009)
Chronic graft-versus-host disease.
S. Lee (2003)
Brocklehurst's Textbook of Geriatric Medicine and Gerontology
D. Stott (2017)
Chronic graft versus host disease.
M. Higman (2004)
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report
F. Ostronoff (2013)
Debating the oncologist's role in defining the value of cancer care: we have a duty to society.
R. Jagsi (2014)
Therapy for hematologic malignancies in older patients , quality of life and health economicsdif fi cult decisions
HJ Deeg (2014)
A Risk Score for Mortality after Allogeneic Hematopoietic Cell Transplantation
Tanyalak Parimon (2006)
Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia
K. Ballen (1997)
Age and acute myeloid leukemia.
F. Appelbaum (2006)
Developing a service model that integrates palliative care throughout cancer care: the time is now.
A. Partridge (2014)
Critiquing US health care.
V. Fuchs (2014)
Current challenges to academic health centers.
V. Fuchs (2013)
How I treat the older patient with acute myeloid leukemia.
G. Ossenkoppele (2015)
「緩和ケア」として行われた介入と副次的評価項目であることの限界 (論文を読み,理解する--Early palliative care for patients with metastatic non-small-cell lung cancer)
森田 達也 (2011)
Indication-specific pricing for cancer drugs.
P. Bach (2014)
Vulnerbility in hematology
D Bordessoule (2013)
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
A. Mims (2013)
Association between the Medicare hospice benefit and health care utilization and costs for patients with poor-prognosis cancer.
Z. Obermeyer (2014)
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.
M. Sorror (2014)
Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia.
H. Klepin (2013)
Impact of Cardiovascular Comorbidity on Ovarian Cancer Mortality
E. Shinn (2013)
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.
D. Stirewalt (2006)
Hope and persuasion by physicians during informed consent.
V. Miller (2014)
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
John Koreth (2013)
This paper is referenced by
Psychosocial Management of Patients Undergoing HSCT and Donors of Stem Cells
S. Datta (2020)
Palliative and End-of-Life Care in Myelodysplastic Syndromes
Myles S. Nickolich (2016)
Network geometry of evidence from randomised controlled trials addressing donor selection and source of haematopoietic progenitor cells used in allogeneic transplantation: a systematic scoping review
M. Monaghan (2018)
Quality of Life: A Tiebreaker in CEBPA Double-Mutated Acute Myeloid Leukemia.
A. Rashidi (2016)
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy
P. Srivastava (2016)